AVDL
Avadel Pharmaceuticals plc
Halal Rating :
Last Price
$7.75
Last updated:
Market Cap
-
7D Change
0.0%
1 Year Change
0.0%
Company Overview
Industries
Exchange
Next Earnings Date
Avadel Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing innovative medications for central nervous system disorders. Their lead product is LUMRYZ (sodium oxybate), an extended-release formulation approved by the FDA for the treatment of cataplexy or excessive daytime sleepiness in adults with narcolepsy.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $50.02m | $53.17m | - | $2.82m | 0.00% | 5.30% |
| June 30, 2024 | $41.5m | $56.96m | - | $2.72m | 0.00% | 4.77% |
| March 31, 2024 | $27.18m | $55.8m | - | $2.59m | 0.00% | 4.64% |
Company Impact
Help us evaluate Avadel Pharmaceuticals plc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.